Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

• Published in: Blood Vol. 124; no. 7; pp. 1038 - 1046
• Main Authors: Richardson, Paul G., Baz, Rachid, Wang, Michael, Jakubowiak, Andrzej J., Laubach, Jacob P., Harvey, R. Donald, Talpaz, Moshe, Berg, Deborah, Liu, Guohui, Yu, Jiang, Gupta, Neeraj, Di Bacco, Alessandra, Hui, Ai-Min, Lonial, Sagar
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.08.2014; American Society of Hematology
• Subjects: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Boron Compounds - adverse effects; Boron Compounds - pharmacokinetics; Boron Compounds - therapeutic use; Clinical Trials and Observations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema - chemically induced; Fatigue - chemically induced; Female; Glycine - adverse effects; Glycine - analogs & derivatives; Glycine - pharmacokinetics; Glycine - therapeutic use; Humans; Male; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Nausea - chemically induced; Neoplasm Recurrence, Local; Proteasome Inhibitors - adverse effects; Proteasome Inhibitors - pharmacokinetics; Proteasome Inhibitors - therapeutic use; Thrombocytopenia - chemically induced; Treatment Outcome

Ixazomib is the first investigational oral proteasome inhibitor to be studied clinically. In this phase 1 trial, 60 patients with relapsed/refractory multiple myeloma (median of 4 prior lines of therapy; bortezomib, lenalidomide, thalidomide, and carfilzomib/marizomib in 88%, 88%, 62%, and 5%, respe...